Home > Health Conditions > Diabetes > Januvia (sitagliptin)

Januvia (sitagliptin phosphate)

Related Topics:

• Actos (pioglitazone HCl) / Amaryl (glimepiride) / Avandia (rosiglitazone) / Byetta (exenatide) / Diabeta, Micronase (glyburide) / Farxiga (dapagliflozin) / Glucophage (metformin) / insulin / Invokana (canagliflozin) / Januvia (sitagliptin) / Jardiance (empagliflozin) / Lantus (glargine) / Onglyza (saxagliptin) / Prandin™ (repaglinide) / Precose (acarbose) / Rezulin (troglitazone) / Starlix® (nateglinide) / Symlin (pramlintide acetate) / Victoza (liraglutide)

Where to purchase:

• Sitagliptin at OffshoreRx1.com,  SuperSaverMeds.com or XlPharmacy.

News & Research:

• Januvia (sitagliptin phosphate) - rxlist.com - "By increasing and prolonging active incretin levels, JANUVIA increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner"
• Diabetes Drugs Tied to Less Amyloid, Slowed Cognitive Decline in Alzheimer's - Medscape, 8/11/21 - "Compared to the group not taking a DPP-4 inhibitor, those taking these agents had significantly lower global SUVRs (1.33 vs 1.41; P = .001). These patients also had significantly lower regional Aβ SUVRs (frontal:1.33 vs 1.41; lateral parietal: 1.34 vs 1.42; lateral temporal: 1.33 vs 1.41; and anterior cingulate/posterior cingulate cortices: 1.43 vs 1.53 ... In addition, those taking DPP-4 inhibitors had lower Aβ burden globally and in two regional cortices ― the lateral parietal and lateral temporal ― compared to the nondiabetes group"
• Metformin vs. Sulfonylureas for Diabetes - WebMD, 12/4/09 - "Researchers reported that diabetes patients who used sulfonylureas had a higher risk of death from all causes and a higher risk of heart failure than diabetes patients who used the most widely prescribed diabetes drug, metformin ... Compared with metformin, also known as Glucophage, single-drug treatment with first- and second-generation sulfonylureas was associated with up to a 61% increased risk for death. Users of second-generation sulfonylureas had up to a 30% higher risk for congestive heart failure ... Patients treated with Actos or Avandia did not appear to have a greater risk for heart attacks than those treated with metformin"
• Two-Year Sitagliptin With or Without Metformin Shows Strong and Durable Effects in Type 2 Diabetes - Doctor's Guide, 9/10/08
• FDA Approves New Treatment for Diabetes - Doctor's Guide, 10/17/07 - "Januvia prolongs the activity of proteins that increase the release of insulin after blood sugar rises, such as after a meal. Januvia does this by blocking an enzyme (dipeptidyl peptidase IV or DPP-IV) which breaks down these proteins, leading to better blood sugar control"
• FDA Approves Once-Daily Januvia(TM) (Sitagliptin Phosphate), the First and Only DPP-4 Inhibitor Available in the United States for Type 2 Diabetes - Doctor's Guide, 10/18/06 - "By adding Januvia to the insulin sensitizers metformin or pioglitazone (a TZD), the three key defects of type 2 diabetes can be addressed: insulin resistance, beta-cell dysfunction (decreased insulin release), and alpha-cell dysfunction (unsuppressed hepatic glucose production)"
• FDA OKs New Type 2 Diabetes Drug - WebMD, 10/17/06
• New oral diabetes drug gets FDA approval - MSNBC, 10/17/06 - "The Food and Drug Administration said it approved Januvia, which enhances the body’s own ability to lower blood sugar levels, after clinical trials showing the new pill works just as well as older diabetes drugs, but with fewer side effects like weight gain"

Abstracts:

• Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for The Treatment of Type 2 Diabetes Mellitus (January) - Ann Pharmacother. 2006 Dec 26
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study - Clin Ther. 2006 Oct;28(10):1556-68
• Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes - Int J Clin Pract. 2006 Dec 5
• Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes - Curr Med Res Opin. 2006 Oct;22(10):1939-47 - "In this study, co-administration of sitagliptin and metformin was generally well tolerated in patients with type 2 diabetes and did not meaningfully alter the steady-state pharmacokinetics of either agent"

Related Sites:

• Doctor's Guide search of Januvia
• Doctor's Guide search of Januvia or sitagliptin
• DrugStore.com price of Januvia
• Life Extension Foundation search
• Medline search of sitagliptin
• Medscape search of Januvia or sitagliptin
• Nutrition Science News search
• RxList search of sitagliptin
• WebMD search of sitagliptin

70526